Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNAseq of NT2.5 and NT2.5-LM breast tumors

ABSTRACT: scRNAseq of NT2.5 and NT2.5-LM breast tumors

PROVIDER: PRJNA1086172 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28284509.fastq.gz	Fastqsanger.gz
	SRR28284510.fastq.gz	Fastqsanger.gz
	SRR28284511.fastq.gz	Fastqsanger.gz
	SRR28284512.fastq.gz	Fastqsanger.gz
	SRR28284513.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

scRNAseq of NT2.5 and NT2.5-LM breast tumors

Project description:Syngeneic NT2.5 and NT2.5-LM breast tumors established in female NeuN mice were collected and sent for scRNAseq to examine various cell populations

2024-06-30 | GSE261252 | GEO

Primary breast tumors

Project description:Primary breast tumors

| PRJNA324252 | ENA

Janibacter sp. LM strain:LM

Project description:Janibacter sp. LM strain:LM Genome sequencing

| PRJNA1108354 | ENA

Melanoma GEMM Tumors, untreated or vemurafenib treated (scRNASeq)

Project description:Melanoma GEMM Tumors, untreated or vemurafenib treated (scRNASeq)

| PRJNA523031 | ENA

RNAseq and scRNAseq analysis of UPFL mouse tumors

Project description:RNAseq and scRNAseq analysis of UPFL mouse tumors

| PRJNA896928 | ENA

Liver metastases originating from 4 colorectal cancer patients (CRC-LM).

Project description:Using liver metastases from 4 colorectal cancer patients (CRC-LM), we explored one receptor: EGFR whose signaling triggers cell proliferation and is exacerbated in many tumors.

2023-06-14 | GSE217414 | GEO

Whole exome sequencing of NT2.5 and NT2.5-LM cell lines

Project description:NT2.5-LM is a cell line derived from the parental NT2.5 cell line that provides a more proliferative and metastatic murine model of breast cancer. We used whole exome sequencing to examine mutational differences.

2024-06-30 | GSE261253 | GEO

LM resistance

Project description:The combination therapy of the Artemisinin-derivative Artemether (ART) with Lumefantrine (LM) (Coartem®) is an important malaria treatment regimen in many endemic countries. Resistance to Artemisinin has already been reported, and it is feared that LM resistance (LMR) could also evolve quickly. Therefore molecular markers which can be used to track Coartem®efficacy are urgently needed. Often, stable resistance arises from initial, unstable phenotypes that can be identified in vitro. Here we have used the Plasmodium falciparum multidrug resistant reference strain V1S to induce LMR in vitro by culturing the parasite under continuous drug pressure for 16 months. The initial IC50 (inhibitory concentration that kills 50% of the parasite population) was 24 nM. The resulting resistant strain V1SLM, obtained after culture for an estimated 166 cycles under LM pressure, grew steadily in 378 nM of LM; this corresponds to 15 times the IC50 of the parental strain. However, after two weeks of culturing V1SLM in drug-free medium, the IC50 returned to that of the initial, parental strain V1S. This transient drug tolerance was associated with major changes in gene expression profiles: when we explored V1SLM using the PFSANGER Affymetrix custom array, we identified 184 differentially expressed (DE) genes; amongst those 18 putative transporters including the multidrug resistance gene (pfmdr1), the multidrug resistance associated protein (pfmrp1) and the V-type H+ pumping pyrophosphatase 2 (pfvp2). Moreover, our results showed significant enrichment of genes associated with fatty acid metabolism and a clear selective advantage for two genomic loci in parasites grown under LM drug pressure, suggesting these genes may contribute to LM response in P. falciparum and could prove useful as molecular markers to monitor LM susceptibility.

2011-04-01 | E-TABM-1101 | biostudies-arrayexpress

Breast cancer tumors

Project description:The project analyzed 88 breast cancer clinical samples, including lymph node negative and positive primary tumors, lymph node metastases, and healthy tissue as control. All samples were combined with a super-SILAC mix that served as an internal standard for quantification.

2016-06-16 | MSV000079830 | MassIVE

Porphyrobacter sp. LM 6 strain:LM 6

Project description:Porphyrobacter sp. LM 6 strain:LM 6 Genome sequencing and assembly

| PRJNA340879 | ENA